MedPath

Vascular function in polycystic ovary patients after treatment with metformin: it’s role in polycystic-ovary-syndrome-associated insulin resistance.

Completed
Conditions
polycystic ovary syndrome
Registration Number
NL-OMON28442
Lead Sponsor
VU University Medical Center, Amsterdam, the Netherlands
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

1. PCOS as judged in early routine patient work-up by 3 out of the following 4 criteria:

a. Oligo (mean length of the menstrual cycle > 35 days) - or amenorrhoea (based on history of oligomenorrhoea);

Exclusion Criteria

1. Cardiovascular disease (hypertension (>160/90 mmHg), stroke, coronary artery disease, peripheral vascular disease, heart failure);

2. Diabetes mellitus (according to ADA criteria);

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Vascular function after metformin therapy compared to vascular function at baseline (micro and macrovascular measurements).
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath